These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 31522955)

  • 1. Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases.
    Zhou Z; Austin GL; Shaffer R; Armstrong DD; Gentry MS
    Trends Mol Med; 2019 Dec; 25(12):1094-1109. PubMed ID: 31522955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological glycogen storage diseases and emerging therapeutics.
    Colpaert M; Singh PK; Donohue KJ; Pires NT; Fuller DD; Corti M; Byrne BJ; Sun RC; Vander Kooi CW; Gentry MS
    Neurotherapeutics; 2024 Sep; 21(5):e00446. PubMed ID: 39277505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.
    Brewer MK; Uittenbogaard A; Austin GL; Segvich DM; DePaoli-Roach A; Roach PJ; McCarthy JJ; Simmons ZR; Brandon JA; Zhou Z; Zeller J; Young LEA; Sun RC; Pauly JR; Aziz NM; Hodges BL; McKnight TR; Armstrong DD; Gentry MS
    Cell Metab; 2019 Oct; 30(4):689-705.e6. PubMed ID: 31353261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-cytokine fusion proteins.
    Kontermann RE
    Arch Biochem Biophys; 2012 Oct; 526(2):194-205. PubMed ID: 22445675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.
    Müller D
    BioDrugs; 2014 Apr; 28(2):123-31. PubMed ID: 24018469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel method for detection of glycogen in cells.
    Skurat AV; Segvich DM; DePaoli-Roach AA; Roach PJ
    Glycobiology; 2017 May; 27(5):416-424. PubMed ID: 28077463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
    Bagshawe KD; Sharma SK; Begent RH
    Expert Opin Biol Ther; 2004 Nov; 4(11):1777-89. PubMed ID: 15500406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen storage diseases.
    Hannah WB; Derks TGJ; Drumm ML; Grünert SC; Kishnani PS; Vissing J
    Nat Rev Dis Primers; 2023 Sep; 9(1):46. PubMed ID: 37679331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting: the ADEPT story so far.
    Bagshawe KD
    Curr Drug Targets; 2009 Feb; 10(2):152-7. PubMed ID: 19199911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-enzyme conjugates for cancer therapy.
    Melton RG; Sherwood RF
    J Natl Cancer Inst; 1996 Feb; 88(3-4):153-65. PubMed ID: 8632489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease.
    Blakey DC; Burke PJ; Davies DH; Dowell RI; Melton RG; Springer CJ; Wright AF
    Biochem Soc Trans; 1995 Nov; 23(4):1047-50. PubMed ID: 8654679
    [No Abstract]   [Full Text] [Related]  

  • 14. The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics.
    Qian L; Lin X; Gao X; Khan RU; Liao JY; Du S; Ge J; Zeng S; Yao SQ
    Chem Rev; 2023 Jun; 123(12):7782-7853. PubMed ID: 37186942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
    Sharma SK; Bagshawe KD
    Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates.
    Lu G; Nishio N; van den Berg NS; Martin BA; Fakurnejad S; van Keulen S; Colevas AD; Thurber GM; Rosenthal EL
    Nat Commun; 2020 Nov; 11(1):5667. PubMed ID: 33168818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coming-of-Age of Antibodies in Cancer Therapeutics.
    Ayyar BV; Arora S; O'Kennedy R
    Trends Pharmacol Sci; 2016 Dec; 37(12):1009-1028. PubMed ID: 27745709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
    Kishnani PS; Goldstein J; Austin SL; Arn P; Bachrach B; Bali DS; Chung WK; El-Gharbawy A; Brown LM; Kahler S; Pendyal S; Ross KM; Tsilianidis L; Weinstein DA; Watson MS;
    Genet Med; 2019 Apr; 21(4):772-789. PubMed ID: 30659246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies and associates: Partners in targeted drug delivery.
    Kennedy PJ; Oliveira C; Granja PL; Sarmento B
    Pharmacol Ther; 2017 Sep; 177():129-145. PubMed ID: 28315359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme therapy for hypertrophic cardiomyopathy in non-classical Pompe disease: Effectiveness of treatment.
    Kim J; Kim H; Eun LY
    Pediatr Int; 2017 Jan; 59(1):107-108. PubMed ID: 28102630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.